This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Acute lymphoblastic leukemia (ALL)	B cell CLL lymphoma 6 (BCL6)	Cell culture and mouse studies suggest inhibiting BCL6 could help treat Gleevec- and Tasigna-resistant ALL. In primary ALL cells, Gleevec plus a peptide inhibitor of BCL6 induced cell death and prevented Gleevec resistance compared with Gleevec alone. In a xenograft mouse model of ALL, Tasigna plus a peptide inhibitor of BCL6 increased survival compared with Tasigna alone. Next steps include studying the role of BCL6 in chronic myeloid leukemia (CML). Novartis AG's Tasigna nilotinib and Gleevec imatinib are marketed to treat ALL and other cancers.	Patent and licensing status undisclosed	Duy, C. <i>et al. Nature</i> ; published online May 18, 2011; doi:10.1038/nature09883 Contact: Markus Müschen, University of California, San Francisco, Calif. e-mail: Markus.Muschen@ucsf.edu
SciBX 4(22); doi:10.1038/scibx.2011.621 Published online June 2, 2011				